Tirzepatide reduces the predicted risk of developing type 2 diabetes in people with obesity or overweight: Post hoc analysis of the SURMOUNT-1 trial.

Hankosky ER, Wang H, Neff LM, Kan H, Wang F, Ahmad NN, Stefanski A, Garvey WT

Diabetes, obesity & metabolism12 Sept 2023Cited by 37 (Europe PMC)

PMID37700443DOI10.1111/dom.15269PepBankPUB-37700443

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with obesity or overweight, tirzepatide 5 mg reduced the 10-year predicted risk score of type 2 diabetes more than placebo at week 72.
In plain wordsIn adults with obesity or overweight, tirzepatide 5 mg cut the predicted 10-year risk of type 2 diabetes more than placebo.
Peptide
Tirzepatide
Outcome
DecreaseAbsolute change in 10-year predicted T2D risk score at week 72, 5 mg
Study
n: not reported in source
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
5 mg · 72 weeksAs given in this study (human).
Measurements
Mean absolute risk score reduction
12.4%
tirzepatide 5 mg
Mean absolute risk score reduction
0.7%
placebo
Source sentences
Summary
At week 72, mean absolute T2D predicted risk score reductions were significantly greater in tirzepatide groups (5 mg, 12.4%; 10 mg, 14.4%; 15 mg, 14.7%) versus placebo (0.7%).
1 context sentence(design, population, supporting numbers)
Summary · context
In this post hoc analysis of SURMOUNT-1, the Cardiometabolic Disease Staging risk engine was used to calculate the 10-year predicted risk of T2D at baseline, week 24 and week 72 among participants randomized to receive 5, 10, or 15 mg tirzepatide or placebo.
Report a problemFND-3770044301
02HumanRandomized controlled trialEfficacy outcome
In adults with obesity or overweight, tirzepatide 10 mg reduced the 10-year predicted risk score of type 2 diabetes more than placebo at week 72.
In plain wordsIn adults with obesity or overweight, tirzepatide 10 mg cut the predicted 10-year risk of type 2 diabetes more than placebo.
Peptide
Tirzepatide
Outcome
DecreaseAbsolute change in 10-year predicted T2D risk score at week 72, 10 mg
Study
n: not reported in source
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
10 mg · 72 weeksAs given in this study (human).
Measurements
Mean absolute risk score reduction
14.4%
tirzepatide 10 mg
Mean absolute risk score reduction
0.7%
placebo
Source sentences
Summary
At week 72, mean absolute T2D predicted risk score reductions were significantly greater in tirzepatide groups (5 mg, 12.4%; 10 mg, 14.4%; 15 mg, 14.7%) versus placebo (0.7%).
1 context sentence(design, population, supporting numbers)
Summary · context
In this post hoc analysis of SURMOUNT-1, the Cardiometabolic Disease Staging risk engine was used to calculate the 10-year predicted risk of T2D at baseline, week 24 and week 72 among participants randomized to receive 5, 10, or 15 mg tirzepatide or placebo.
Report a problemFND-3770044302
03HumanRandomized controlled trialEfficacy outcome
In adults with obesity or overweight, tirzepatide 15 mg reduced the 10-year predicted risk score of type 2 diabetes more than placebo at week 72.
In plain wordsIn adults with obesity or overweight, tirzepatide 15 mg cut the predicted 10-year risk of type 2 diabetes more than placebo.
Peptide
Tirzepatide
Outcome
DecreaseAbsolute change in 10-year predicted T2D risk score at week 72, 15 mg
Study
n: not reported in source
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
15 mg · 72 weeksAs given in this study (human).
Measurements
Mean absolute risk score reduction
14.7%
tirzepatide 15 mg
Mean absolute risk score reduction
0.7%
placebo
Source sentences
Summary
At week 72, mean absolute T2D predicted risk score reductions were significantly greater in tirzepatide groups (5 mg, 12.4%; 10 mg, 14.4%; 15 mg, 14.7%) versus placebo (0.7%).
1 context sentence(design, population, supporting numbers)
Summary · context
In this post hoc analysis of SURMOUNT-1, the Cardiometabolic Disease Staging risk engine was used to calculate the 10-year predicted risk of T2D at baseline, week 24 and week 72 among participants randomized to receive 5, 10, or 15 mg tirzepatide or placebo.
Report a problemFND-3770044303
04HumanRandomized controlled trialEfficacy outcome
In adults with obesity or overweight, median relative reductions in predicted type 2 diabetes risk with tirzepatide at week 72 ranged from 60.3% to 69.0%.
In plain wordsIn adults with obesity or overweight, tirzepatide cut predicted type 2 diabetes risk by a median of 60.3% to 69.0% at week 72.
Peptide
Tirzepatide
Outcome
DecreaseMedian relative reduction in predicted T2D risk at week 72
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
5, 10 or 15 mg · 72 weeksAs given in this study (human).
Measurements
Median relative risk reduction
60.3 to 69%
tirzepatide groups
Source sentences
Summary
At week 72, median relative predicted risk reductions following tirzepatide treatment ranged from 60.3% to 69.0%.
1 context sentence(design, population, supporting numbers)
Summary · context
In this post hoc analysis of SURMOUNT-1, the Cardiometabolic Disease Staging risk engine was used to calculate the 10-year predicted risk of T2D at baseline, week 24 and week 72 among participants randomized to receive 5, 10, or 15 mg tirzepatide or placebo.
Report a problemFND-3770044304
05HumanRandomized controlled trialEfficacy outcome
In adults with obesity or overweight and prediabetes, tirzepatide reduced predicted type 2 diabetes risk significantly more than placebo.
In plain wordsIn adults with obesity or overweight and prediabetes, tirzepatide cut predicted type 2 diabetes risk more than placebo.
Peptide
Tirzepatide
Outcome
DecreasePredicted T2D risk reduction in participants with prediabetes
Study
n: not reported in source
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
5, 10 or 15 mgAs given in this study (human).
Source sentences
Summary
For participants with and without prediabetes, risk reductions were significantly greater in tirzepatide groups versus placebo.
1 context sentence(design, population, supporting numbers)
Summary · context
In this post hoc analysis of SURMOUNT-1, the Cardiometabolic Disease Staging risk engine was used to calculate the 10-year predicted risk of T2D at baseline, week 24 and week 72 among participants randomized to receive 5, 10, or 15 mg tirzepatide or placebo.
Report a problemFND-3770044305
06HumanRandomized controlled trialEfficacy outcome
In adults with obesity or overweight and without prediabetes, tirzepatide reduced predicted type 2 diabetes risk significantly more than placebo.
In plain wordsIn adults with obesity or overweight and without prediabetes, tirzepatide cut predicted type 2 diabetes risk more than placebo.
Peptide
Tirzepatide
Outcome
DecreasePredicted T2D risk reduction in participants without prediabetes
Study
n: not reported in source
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
5, 10 or 15 mgAs given in this study (human).
Source sentences
Summary
For participants with and without prediabetes, risk reductions were significantly greater in tirzepatide groups versus placebo.
1 context sentence(design, population, supporting numbers)
Summary · context
In this post hoc analysis of SURMOUNT-1, the Cardiometabolic Disease Staging risk engine was used to calculate the 10-year predicted risk of T2D at baseline, week 24 and week 72 among participants randomized to receive 5, 10, or 15 mg tirzepatide or placebo.
Report a problemFND-3770044306
07HumanRandomized controlled trialEfficacy outcome
At week 72, tirzepatide-treated participants with prediabetes had greater mean risk score reductions than those without prediabetes.
In plain wordsOn tirzepatide, people with prediabetes had larger drops in predicted diabetes risk than people without prediabetes.
Peptide
Tirzepatide
Outcome
DecreasePredicted T2D risk reduction, prediabetes vs no prediabetes
Study
n: not reported in source
Comparator
Participants without prediabetes
Outcome group
Glycemic control · Metabolic and weight
Studied dose
5, 10 or 15 mg · 72 weeksAs given in this study (human).
Measurements
Mean risk score reduction
16 to 20.3%
with prediabetes
Mean risk score reduction
10.1 to 11.3%
without prediabetes
Source sentences
Summary
At week 72, participants with prediabetes (range: 16.0%-20.3%) had greater mean risk score reductions from baseline versus those without prediabetes (range: 10.1%-11.3%).
1 context sentence(design, population, supporting numbers)
Summary · context
In this post hoc analysis of SURMOUNT-1, the Cardiometabolic Disease Staging risk engine was used to calculate the 10-year predicted risk of T2D at baseline, week 24 and week 72 among participants randomized to receive 5, 10, or 15 mg tirzepatide or placebo.
Report a problemFND-3770044307
08HumanRandomized controlled trialEfficacy outcome
Across baseline body mass index subgroups, tirzepatide reduced predicted type 2 diabetes risk significantly more than placebo.
In plain wordsIn adults with obesity or overweight, tirzepatide cut predicted type 2 diabetes risk more than placebo in every body mass index group.
Peptide
Tirzepatide
Outcome
DecreasePredicted T2D risk reduction across BMI subgroups
Study
n: not reported in source
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
5, 10 or 15 mgAs given in this study (human).
Source sentences
Summary
Across body mass index subgroups, mean reductions from baseline were significantly greater in tirzepatide groups versus placebo.
1 context sentence(design, population, supporting numbers)
Summary · context
In this post hoc analysis of SURMOUNT-1, the Cardiometabolic Disease Staging risk engine was used to calculate the 10-year predicted risk of T2D at baseline, week 24 and week 72 among participants randomized to receive 5, 10, or 15 mg tirzepatide or placebo.
Report a problemFND-3770044308

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT04184622

A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight

Eli Lilly and Companyn = 2,5394 Dec 2019 to 6 Jul 2024

Overweight · Obesity

Trial page ClinicalTrials.govUpdated 24 Jul 2025

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:58 UTC
Study results updated
Version 1
9 Oct 2026, 03:07 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.